| Aug 28 |
BridgeBio Pharma to Participate in September Investor Events
|
| Aug 26 |
BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence
|
| Aug 22 |
BridgeBio: PDUFA Date Expected In November 2024 Could Shift Momentum
|
| Aug 21 |
BridgeBio forms joint venture GondolaBio for rare disease assets
|
| Aug 21 |
BridgeBio sends rare disease drugs to new company
|
| Aug 19 |
BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
|
| Aug 17 |
BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon
|
| Aug 3 |
BridgeBio Pharma Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Aug 1 |
BridgeBio Pharma GAAP EPS of -$0.59
|
| Aug 1 |
BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates
|
